FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989038715> ?p ?o ?g. }

• W2989038715 endingPage "1798" @default.
• W2989038715 startingPage "1798" @default.
• W2989038715 abstract "Background Treatment of Multiple Myeloma (MM) has reached a point at which cure for a subset of patients becomes feasible. Still, resistance to therapy is a major challenge in the management of MM patients. Underlying resistance are the emergence of subclones, different to those found at diagnosis. Assessing the mutation status of recurrently mutated genes in MM can assist in tracking those subclones. In this study, we aimed to estimate the clonal composition by performing next generation sequencing in a set of samples from newly diagnosed patients included in a transplant-eligible trial (EMN02, Cavo et al., Blood 2017 130:397), and repeating this analysis in paired samples obtained at relapse when these patients were treated with Carfilzomib/ Pomalidomide/ Dexamethasone in the EMN11 trial (Sonneveld et al., Blood 2018 132:801). Materials and methods Panel-Seq was performed for a subset of most frequently recurring genes in MM (NRAS, KRAS, BRAF, DIS3, FAM46C and TP53). For 21 patients, DNA from bone marrow derived MM cells was available at diagnosis (EMN02/HOVON-95) and at relapse (EMN11/HOVON-114). For an additional 24 patients material at relapse was available (EMN11); survival data were available of 38/45 EMN11 cases. Endpoints were response, progression-free survival (PFS) and overall survival (OS). Response categories were stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR) and stable disease (SD). All samples had a sample purity > 53% (median 98% (53-100%)). Results Using an allelic fraction of more than 1%, NRAS mutations were found in 48% of diagnostic samples, and in 43% of relapse samples (Figure 1). Overall, KRAS mutations were less frequent at relapse compared to diagnosis (24% vs 43% at diagnosis). In contrast, mutations in TP53 were found more frequently at relapse compared to diagnosis (in 2 patients at relapse (10%), compared to none at diagnosis). BRAF mutations were found in 4 patients at diagnosis and 2 at relapse (19% vs 10%). An allelic fraction of 40% or higher may be used to indicate clonality, i.e. all cells in the tumor are affected. For NRAS, this was observed at diagnosis and at relapse, in 5/10 and 5/9, and for KRAS, in 4/9 and 3/6, respectively. In 9 out of 21 patients with paired samples identical NRAS mutations were detected at both time points. In 4 of these cases the estimated clone size of the NRAS mutation had increased at the time of relapse, while in 5 cases the clone remained similar in size. Four out of 6 cases with a stable clone size or diminishing NRAS clone had achieved sCR/CR with first-line treatment whereas all cases with increasing NRAS clone size were VGPR or worse (p=0.08). Interestingly, out of 19 cases with known survival data in the EMN11 trial, 2 out of 3 cases with an increase of 40% or more in NRAS clone size demonstrated an OS of less than 6 months, compared to only 1 out of 16 remaining cases. Four cases demonstrated both NRAS and KRAS mutations at diagnosis. In three of these cases, the KRAS mutation was not detected at relapse. In total, 5 pairs showed KRAS mutations at diagnosis and relapse. BRAF mutations were found in 4 cases at diagnosis; in two of these, both V600E, the mutation was also detected at relapse. None of the clonal shifts in genes other than NRAS demonstrated an association with PFS, OS or response. Of the 45 patients analysed at entry in the EMN11 trial with an variant allelic frequency of 1% or higher, KRAS mutations were found in 36% of cases, followed by NRAS (29%), FAM46C (16%), BRAF (11%), TP53 (7%) and DIS3 (4%). Clonal NRAS mutations at baseline EMN11 cases were associated with worse OS but not PFS (median OS of clonal NRAS patients: 5 months compared to not reached for remaining patients; log rank p<0.05). Conclusion Although limited in patient size and number of genes studied, this unique cohort of homogeneously treated patients through 1st ánd 2nd line treatment allowed clinical analysis of mutations detected with high sensitivity to a variant allelic frequency of 1%. Sequential sequencing analysis has limited predictive value for 2nd line response, PFS and OS. Only an increase in NRAS clone size may be associated with worse survival, which requires validation in different datasets. In RRMM, clonal NRAS mutations may represent an additional risk factor. Disclosures Broijl: Takeda: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Celgene: Honoraria. Zweegman:Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding. Minnema:Celgene Corporation: Honoraria, Research Funding; Amgen: Honoraria; Servier: Honoraria; Gilead: Honoraria; Jansen Cilag: Honoraria. Boccadoro:Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; AbbVie: Honoraria; Mundipharma: Research Funding; Sanofi: Honoraria, Research Funding. Sonneveld:Amgen: Honoraria, Research Funding; BMS: Honoraria; Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Karyopharm: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; SkylineDx: Research Funding." @default.
• W2989038715 created "2019-11-22" @default.
• W2989038715 creator A5002972322 @default.
• W2989038715 creator A5018139001 @default.
• W2989038715 creator A5020489305 @default.
• W2989038715 creator A5025823091 @default.
• W2989038715 creator A5047666215 @default.
• W2989038715 creator A5049413660 @default.
• W2989038715 creator A5052162573 @default.
• W2989038715 creator A5068940705 @default.
• W2989038715 creator A5073710610 @default.
• W2989038715 creator A5083385949 @default.
• W2989038715 creator A5089637265 @default.
• W2989038715 date "2019-11-13" @default.
• W2989038715 modified "2023-09-26" @default.
• W2989038715 title "Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials" @default.
• W2989038715 doi "https://doi.org/10.1182/blood-2019-130086" @default.
• W2989038715 hasPublicationYear "2019" @default.
• W2989038715 type Work @default.
• W2989038715 sameAs 2989038715 @default.
• W2989038715 citedByCount "0" @default.
• W2989038715 crossrefType "journal-article" @default.
• W2989038715 hasAuthorship W2989038715A5002972322 @default.
• W2989038715 hasAuthorship W2989038715A5018139001 @default.
• W2989038715 hasAuthorship W2989038715A5020489305 @default.
• W2989038715 hasAuthorship W2989038715A5025823091 @default.
• W2989038715 hasAuthorship W2989038715A5047666215 @default.
• W2989038715 hasAuthorship W2989038715A5049413660 @default.
• W2989038715 hasAuthorship W2989038715A5052162573 @default.
• W2989038715 hasAuthorship W2989038715A5068940705 @default.
• W2989038715 hasAuthorship W2989038715A5073710610 @default.
• W2989038715 hasAuthorship W2989038715A5083385949 @default.
• W2989038715 hasAuthorship W2989038715A5089637265 @default.
• W2989038715 hasBestOaLocation W29890387151 @default.
• W2989038715 hasConcept C121608353 @default.
• W2989038715 hasConcept C126322002 @default.
• W2989038715 hasConcept C143998085 @default.
• W2989038715 hasConcept C21790070 @default.
• W2989038715 hasConcept C2776063141 @default.
• W2989038715 hasConcept C2776364478 @default.
• W2989038715 hasConcept C2778524551 @default.
• W2989038715 hasConcept C2778684742 @default.
• W2989038715 hasConcept C2778822529 @default.
• W2989038715 hasConcept C2779134260 @default.
• W2989038715 hasConcept C2780108899 @default.
• W2989038715 hasConcept C2780739268 @default.
• W2989038715 hasConcept C2781187634 @default.
• W2989038715 hasConcept C3019894029 @default.
• W2989038715 hasConcept C526805850 @default.
• W2989038715 hasConcept C71924100 @default.
• W2989038715 hasConceptScore W2989038715C121608353 @default.
• W2989038715 hasConceptScore W2989038715C126322002 @default.
• W2989038715 hasConceptScore W2989038715C143998085 @default.
• W2989038715 hasConceptScore W2989038715C21790070 @default.
• W2989038715 hasConceptScore W2989038715C2776063141 @default.
• W2989038715 hasConceptScore W2989038715C2776364478 @default.
• W2989038715 hasConceptScore W2989038715C2778524551 @default.
• W2989038715 hasConceptScore W2989038715C2778684742 @default.
• W2989038715 hasConceptScore W2989038715C2778822529 @default.
• W2989038715 hasConceptScore W2989038715C2779134260 @default.
• W2989038715 hasConceptScore W2989038715C2780108899 @default.
• W2989038715 hasConceptScore W2989038715C2780739268 @default.
• W2989038715 hasConceptScore W2989038715C2781187634 @default.
• W2989038715 hasConceptScore W2989038715C3019894029 @default.
• W2989038715 hasConceptScore W2989038715C526805850 @default.
• W2989038715 hasConceptScore W2989038715C71924100 @default.
• W2989038715 hasIssue "Supplement_1" @default.
• W2989038715 hasLocation W29890387151 @default.
• W2989038715 hasOpenAccess W2989038715 @default.
• W2989038715 hasPrimaryLocation W29890387151 @default.
• W2989038715 hasRelatedWork W2041302492 @default.
• W2989038715 hasRelatedWork W2050991415 @default.
• W2989038715 hasRelatedWork W2056322049 @default.
• W2989038715 hasRelatedWork W2056911298 @default.
• W2989038715 hasRelatedWork W2144797350 @default.
• W2989038715 hasRelatedWork W2203736367 @default.
• W2989038715 hasRelatedWork W2344741804 @default.
• W2989038715 hasRelatedWork W2989038715 @default.
• W2989038715 hasRelatedWork W3212164369 @default.
• W2989038715 hasRelatedWork W4286296009 @default.
• W2989038715 hasVolume "134" @default.
• W2989038715 isParatext "false" @default.
• W2989038715 isRetracted "false" @default.
• W2989038715 magId "2989038715" @default.
• W2989038715 workType "article" @default.